Saturday 17 October 2026
Export AKAN’s income statement to Excel — free account
Akanda Corp.
AKAN Healthcare Drug Manufacturers Specialty & Generic
Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024. Insiders bought in the last twelve months.
1.20
0.11
−8.40%
Follow AKAN
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% |
+7 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (18.24) | (8.45) | (12.32) | |
Capital Expenditures |
— | (4.57) | — | (3.33) | |
| Other line items | |||||
Cash ROIC |
0.00% | (1,209.79%) | (138.82%) | (145.41%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.17 | 2.10 | 3.04 | |
Capex/Depreciation |
— | (3.54) | 0.00 | (0.46) | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | — | 0.00 | |
Capex to Sales |
— | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026